Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,924 INR
Change Today +9.60 / 0.50%
Volume 212.6K
CDH On Other Exchanges
Symbol
Exchange
Natl India
As of 7:05 AM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

cadila healthcare ltd (CDH) Snapshot

Open
1,918
Previous Close
1,915
Day High
1,978
Day Low
1,890
52 Week High
07/17/15 - 2,045
52 Week Low
07/31/14 - 1,045
Market Cap
394.0B
Average Volume 10 Days
117.9K
EPS TTM
56.20
Shares Outstanding
204.7M
EX-Date
07/30/15
P/E TM
34.2x
Dividend
12.00
Dividend Yield
0.47%
Current Stock Chart for CADILA HEALTHCARE LTD (CDH)

Related News

No related news articles were found.

cadila healthcare ltd (CDH) Related Businessweek News

No Related Businessweek News Found

cadila healthcare ltd (CDH) Details

Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients, veterinary, and human formulations. The company offers branded formulations in the therapeutic areas of neurological, neutraceutical, pain management, gastro intestinal, respiratory, anti-infective, biological, cardiovascular, female healthcare, dermatology, and others. It also provides consumer wellness products, such as Sugar Free, a low calorie sugar substitute; EverYuth, a range of skincare products; and Nutralite, a cholesterol free table spread. In addition, the company researches and develops a pipeline of 24 biologics comprising 20 biosimilars and 4 novel biological products; and new drugs in cardio-metabolic, inflammation, pain, and oncology therapeutic areas. Further, it provides animal healthcare products. Additionally, the company develops vaccines that are designed to address infectious diseases, including next-generation influenza, measles-mumps-rubella-varicella, typhoid, DPT-HiB, hepatitis-B, hepatitis-A, hepatitis-E, Japanese encephalitis, HPV, and combination vaccines. The company was founded in 1952 and is headquartered in Ahmedabad, India.

Founded in 1952

cadila healthcare ltd (CDH) Top Compensated Officers

Chairman, Managing Director, Chairman of Shar...
Total Annual Compensation: 148.3M
Chief Financial Officer and Member of Risk Ma...
Total Annual Compensation: 25.6M
Deputy Managing Director, Director, Member of...
Total Annual Compensation: 100.0M
Compliance Officer and Company Secretary
Total Annual Compensation: 2.5M
Compensation as of Fiscal Year 2015.

cadila healthcare ltd (CDH) Key Developments

Cadila Healthcare Board Approves Delisting From ASE

The Board of Directors of the Cadila Healthcare Ltd. at its meeting held on May 15, 2015, decided to delist Equity Shares of the Company from Ahmedabad Stock Exchange Limited (ASE), in view of non-trading of Equity Shares of the Company on ASE since last so many years. Further, 204,748,520 Equity Shares of INR 5 each fully paid-up are listed with BSE Ltd. and National Stock Exchange of India Limited having nationwide terminals for trading of the shares of the Company and hence there will not be any inconvenience to any of the shareholders of the Company in trading of the shares of the Company. Further the Company has informed that, the Company will continue listing of Equity Shares of the Company with BSE Ltd and National Stock Exchange of India Limited even after delisting with ASE.

Cadila Healthcare Is Reported To Acquire Injectables Business Of Claris

Cadila Healthcare Limited (BSE:532321) has emerged as the front runner to acquire the generic sterile injectables business of Claris Lifesciences Limited (BSE:533288). Both Cadila and Claris are currently engaged in last-minute due diligence negotiations involving tax and other financial matters, said sources aware of the talks. Cadila is likely to pay a hefty premium, valuing the company at INR 31 billion to INR 34 billion. A formal announcement is expected early June 2015 provided there are no last-minute delays or glitches. The Cadila Healthcare spokesperson told Economic Times that as a matter of policy, the company does not comment on market speculation and a Claris spokesperson, however, denied any such development. Following the report, stock of Claris rallied as much as 17.79% in intraday trade on May 21, 2015.

Cadila Healthcare Limited Announces Audited Consolidated and Company Earnings Results for the Fourth Quarter and Year Ended Mach 31, 2015

Cadila Healthcare Limited announced audited consolidated and company earnings results for the fourth quarter and year ended Mach 31, 2015. For the quarter, on consolidated basis, the company reported net sales of INR 22,471.2 million against INR 19,163.3 million a year ago. Total income from operations (net) was INR 22,471.2 million against INR 19,685.0 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 4,203.3 million against INR 3,057.7 million a year ago. Profit from ordinary activities before tax was INR 4,258.2 million against INR 2,811.8 million a year ago. Net profit from ordinary activities after tax was INR 3,550.7 million or INR 17.11 per basic and diluted share before and after extraordinary items against INR 2,464.2 million or INR 11.68 per basic and diluted share before and after extraordinary items a year ago. For the year, on consolidated basis, the company reported net sales of INR 84,971.2 million against INR 70,600.7 million a year ago. Total income from operations (net) was INR 86,513.4 million against INR 72,240.3 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 14,684.6 million against INR 9,989.1 million a year ago. Profit from ordinary activities before tax was INR 14,455.3 million against INR 9,422.4 million a year ago. Net profit from ordinary activities after tax was INR 11,861.1 million or INR 56.20 per basic and diluted share before and after extraordinary items against INR 8,362.3 million or INR 38.25 per basic and diluted share before and after extraordinary items a year ago. Consolidated CapEx for the year was INR 3.8 billion. Return on net worth increased to 30.1% from 25.6% last year, while the return on capital employed increased to 18.3% from 14.6% last year. Consolidated debt at a gross levels stood at INR 26.5 billion, and debt net of cash stood at INR 19.8 billion. The company net debt equity ratio improved to 0.47 from 0.63 last year For the quarter, on company basis, the company reported net sales of INR 13,375.6 million against INR 9,904.2 million a year ago. Total income from operations (net) was INR 14,539.5 million against INR 11,015.4 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 4,075.7 million against INR 2,427.0 million a year ago. Profit from ordinary activities before tax was INR 4,086.1 million against INR 2,530.4 million a year ago. Net profit from ordinary activities after tax was INR 3,470.6 million or INR 16.95 per basic and diluted share before and after extraordinary items against INR 2,166.8 million or INR 10.58 per basic and diluted share before and after extraordinary items a year ago. For the year, on company basis, the company reported net sales of INR 46,860.9 million against INR 35,245.3 million a year ago. Total income from operations (net) was INR 52,844.3 million against INR 40,421.1 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 13,222.6 million against INR 6,795.9 million a year ago. Profit from ordinary activities before tax was INR 14,646.3 million against INR 9,456.7 million a year ago. Net profit from ordinary activities after tax was INR 12,711.2 million or INR 62.08 per basic and diluted share before and after extraordinary items against INR 9,035.9 million or INR 44.13 per basic and diluted share before and after extraordinary items a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDH:IN 1,924.10 INR +9.60

CDH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cipla Ltd/India 671.90 INR -3.45
Glenmark Pharmaceuticals Ltd 991.15 INR -45.25
Piramal Enterprises Ltd 888.90 INR -34.50
Torrent Pharmaceuticals Ltd 1,397 INR +7.00
Wockhardt Ltd 1,471 INR -24.65
View Industry Companies
 

Industry Analysis

CDH

Industry Average

Valuation CDH Industry Range
Price/Earnings 32.9x
Price/Sales 4.4x
Price/Book 8.9x
Price/Cash Flow 26.3x
TEV/Sales 4.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CADILA HEALTHCARE LTD, please visit www.zyduscadila.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.